keyword
MENU ▼
Read by QxMD icon Read
search

arb vs ace inhibitor in heart failure

keyword
https://www.readbyqxmd.com/read/27754163/sy-11-3-hypertension-in-women-more-dangerous-than-in-men
#1
Suzanne Oparil
Heart disease, stroke, and kidney failure are leading causes of death worldwide, and hypertension is a significant risk factor for each. Hypertension is less common in women, compared to men, in those younger than 45 years of age. This trend is reversed in those 65 years and older. In the US between 2011-2014, the prevalence of hypertension in women and men by age group was 6% vs 8% (18-39 years), 30% vs 35% (40-59 years), and 67% vs 63% (60 years and over). Awareness, treatment, and control rates differ between genders with women being more aware of their diagnosis (85% vs 80%), more likely to take their medications (81% vs 71%) and more frequently having controlled hypertension (55% vs 49%)...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27643473/improving-medication-titration-in-heart-failure-by-embedding-a-structured-medication-titration-plan
#2
Annabel Hickey, Jessica Suna, Louise Marquart, Charles Denaro, George Javorsky, Andrew Munns, Alison Mudge, John J Atherton
BACKGROUND: To improve up-titration of medications to target dose in heart failure patients by improving communication from hospital to primary care. METHODS: This quality improvement project was undertaken within three heart failure disease management (HFDM) services in Queensland, Australia. A structured medication plan was collaboratively designed and implemented in an iterative manner, using methods including awareness raising and education, audit and feedback, integration into existing work practice, and incentive payments...
September 7, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27643118/sy-11-3-hypertension-in-women-more-dangerous-than-in-men
#3
Suzanne Oparil
Heart disease, stroke, and kidney failure are leading causes of death worldwide, and hypertension is a significant risk factor for each. Hypertension is less common in women, compared to men, in those younger than 45 years of age. This trend is reversed in those 65 years and older. In the US between 2011-2014, the prevalence of hypertension in women and men by age group was 6% vs 8% (18-39 years), 30% vs 35% (40-59 years), and 67% vs 63% (60 years and over). Awareness, treatment, and control rates differ between genders with women being more aware of their diagnosis (85% vs 80%), more likely to take their medications (81% vs 71%) and more frequently having controlled hypertension (55% vs 49%)...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27508614/-op-2a-06-current-drug-treatment-of-hypertension-in-sweden-in-relation-to-gender-age-and-comorbidity
#4
F Wallentin, B Wettermark, T Kahan
OBJECTIVE: To describe current antihypertensive drug therapy in Sweden in relation to gender, age, and comorbidity. DESIGN AND METHOD: By use of the Stockholm County Council database, comprising all healthcare consultations, hospitalizations and dispensed drugs for 2.1 million inhabitants living in the Greater Stockholm region in 2013, we identified all persons >20 years with a recorded diagnosis of hypertension during 2009-2013, their comorbidity, and their dispensed antihypertensive drugs during 2013...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27502849/long-term-changes-of-renal-function-in-relation-to-ace-inhibitor-angiotensin-receptor-blocker-dosing-in-patients-with-heart-failure-and-chronic-kidney-disease
#5
Hanna Fröhlich, Christoph Nelges, Tobias Täger, Vedat Schwenger, Rita Cebola, Johannes Schnorbach, Kevin M Goode, Syed Kazmi, Hugo A Katus, John G F Cleland, Andrew L Clark, Lutz Frankenstein
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have become cornerstones of therapy for chronic heart failure (CHF). Guidelines advise high target doses for ACEIs/ARBs, but fear of worsening renal function may limit dose titration in patients with concomitant chronic kidney disease (CKD). METHODS: In this retrospective observational study, we identified 722 consecutive patients with systolic CHF, stable CKD stage III/IV (estimated glomerular filtration rate [eGFR] 15-60 mL min(-1) 1...
August 2016: American Heart Journal
https://www.readbyqxmd.com/read/27378313/renin-angiotensin-system-inhibitors-vs-other-antihypertensives-in-hypertensive-blacks-a-meta-analysis
#6
Mohan Palla, Tomo Ando, Emmanuel Androulakis, Tesfaye Telila, Alexandros Briasoulis
The purpose of this study was to assess the effects of renin-angiotensin system (RAS) inhibitors vs other antihypertensive agents on cardiovascular outcomes in hypertensive black patients. The authors performed a systematic review and meta-analysis of studies that compared the effects of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) with calcium channel blockers (CCBs), diuretics, and β-blockers in hypertensive black patients on cardiovascular outcomes. A total of 38,983 patients with a mean age of 60 years and mean follow-up of 4 years were included in our meta-analysis...
July 4, 2016: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/27347090/delayed-kidney-injury-following-coronary-angiography
#7
Feng Wang, Cheng Peng, Guangyuan Zhang, Qing Zhao, Changyou Xuan, Meng Wei, Niansong Wang
It is occasionally observed that patients without contrast-induced nephropathy (CIN) develop kidney injury within 1-6 months after coronary angiography (CAG), termed delayed CIN or delayed kidney injury (DKI) following CAG. The present study aimed to investigate the associated risk factors of delayed CIN and its possible pathogenesis. Subjects with CAG or coronary stenting from January 2008 to December 2009 were studied. A retrospective survey on DKI after CAG was conducted and the risk factors were analyzed...
July 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27170530/initiating-sacubitril-valsartan-lcz696-in-heart-failure-results-of-titration-a-double-blind-randomized-comparison-of-two-uptitration-regimens
#8
Michele Senni, John J V McMurray, Rolf Wachter, Hugh F McIntyre, Antonio Reyes, Ivan Majercak, Peter Andreka, Nina Shehova-Yankova, Inder Anand, Mehmet B Yilmaz, Harinder Gogia, Manuel Martinez-Selles, Steffen Fischer, Zsolt Zilahi, Franco Cosmi, Valeri Gelev, Enrique Galve, Juanjo J Gómez-Doblas, Jan Nociar, Maria Radomska, Beata Sokolova, Maurizio Volterrani, Arnab Sarkar, Bernard Reimund, Fabian Chen, Alan Charney
AIMS: To assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection fraction ≤35%). METHODS AND RESULTS: A 5-day open-label run-in (sacubitril/valsartan 50 mg twice daily) preceded an 11-week, double-blind, randomization period [100 mg twice daily for 2 weeks followed by 200 mg twice daily ('condensed' regimen) vs. 50 mg twice daily for 2 weeks, 100 mg twice daily for 3 weeks, followed by 200 mg twice daily ('conservative' regimen)]...
September 2016: European Journal of Heart Failure
https://www.readbyqxmd.com/read/27095461/physicians-adherence-to-guideline-recommended-medications-in-heart-failure-with-reduced-ejection-fraction-data-from-the-qualify-global-survey
#9
Michel Komajda, Stefan D Anker, Martin R Cowie, Gerasimos S Filippatos, Bastian Mengelle, Piotr Ponikowski, Luigi Tavazzi
AIMS: To assess physicians' adherence to guideline-recommended medications for the treatment of chronic heart failure (CHF) with reduced ejection fraction. METHODS AND RESULTS: QUALIFY is an international prospective observational longitudinal survey of 7092 CHF outpatients recruited 1-15 months after hospitalization for heart failure from September 2013 to December 2014 in 547 centres in 36 countries. We constructed a five-class guideline adherence score for angiotensin converting enzyme inhibitors (ACEIs), beta-blockers, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists, and ivabradine...
May 2016: European Journal of Heart Failure
https://www.readbyqxmd.com/read/26866934/does-renin-angiotensin-system-blockade-protect-lupus-nephritis-patients-from-atherosclerotic-cardiovascular-events-a-case-control-study
#10
Konstantinos Tselios, Dafna D Gladman, Jiandong Su, Murray B Urowitz
OBJECTIVE: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are used as an adjuvant treatment in lupus nephritis (LN) patients with proteinuria. The primary aim of this study was to discover whether ACE inhibitors/ARBs have an atheroprotective effect similar to other, at-risk, populations. METHODS: A total of 144 patients (cases; mean ± SD age at onset 34 ± 12.1 years, followup 14.9 ± 8.6 years) with LN who were treated with ACE inhibitors/ARBs for at least 5 years were enrolled...
October 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/26763511/angiotensin-converting-enzyme-inhibitors-or-angiotensin-receptor-blockers-in-patients-without-heart-failure-insights-from-254-301-patients-from-randomized-trials
#11
Sripal Bangalore, Robert Fakheri, Bora Toklu, Gbenga Ogedegbe, Howard Weintraub, Franz H Messerli
OBJECTIVES: To compare the efficacy and safety of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. PATIENTS AND METHODS: Meta-analysis of randomized trials identified using PubMed, Embase, and Cochrane Central Register of Controlled Trials searches from January 1, 1980, through April 13, 2015, of ACEis and ARBs compared with placebo or active controls and corroborated with head-to-head trials of ARBs vs ACEis...
January 2016: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/26701233/angiotensin-ii-type-1-receptor-blockers-as-a-first-choice-in-patients-with-acute-myocardial-infarction
#12
Jang Hoon Lee, Myung Hwan Bae, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Won Kee Lee, Myung Ho Jeong, Young Jo Kim, Myeong Chan Cho, Chong Jin Kim, Shung Chull Chae
BACKGROUND/AIMS: Angiotensin II type 1 receptor blockers (ARBs) have not been adequately evaluated in patients without left ventricular (LV) dysfunction or heart failure after acute myocardial infarction (AMI). METHODS: Between November 2005 and January 2008, 6,781 patients who were not receiving angiotensin-converting enzyme inhibitors (ACEIs) or ARBs were selected from the Korean AMI Registry. The primary endpoints were 12-month major adverse cardiac events (MACEs) including death and recurrent AMI...
March 2016: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/26603543/renin-angiotensin-aldosterone-system-inhibition-is-safe-in-the-preoperative-period-surrounding-carotid-endarterectomy
#13
MULTICENTER STUDY
Andrea M Steely, Peter W Callas, Daniel J Bertges
OBJECTIVE: Discontinuation of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) medications before surgery has been suggested because of the potentially deleterious effects of hypotension. We investigated the effect of preoperative ACEI and/or ARB use on early outcomes after carotid endarterectomy (CEA). METHODS: We examined 3752 consecutive CEA patients within the Vascular Study Group of New England from September 2012 to September 2014 and compared outcomes for patients treated (n = 1772) or not treated (n = 1980) with ACEI and/or ARB preoperatively...
March 2016: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/26398149/cac-score-as-a-possible-criterion-for-administration-of-angiotensin-converting-enzyme-inhibitors-and-or-angiotensin-receptor-blockers-the-multiethnic-study-of-atherosclerosis
#14
Sirous Darabian, Yanting Luo, Arman Homat, Khashayar Khosraviani, Nathan Wong, Irfan Zeb, Khurram Nasir, Matthew J Budoff
INTRODUCTION: Several trials have demonstrated that angiotensin converting enzyme inhibitors (ACEIs) decrease cardiovascular (CV) mortality rates in patients with heart failure; however, the Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) and European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) trials failed to show significant similar preventive effects in normal ejection fraction patients. We evaluated the baseline coronary artery calcium (CAC) score as a predictor of the effects of ACEIs/angiotensin receptor blockers (ARBs) on outcomes among normal ejection fraction participants...
December 2015: Coronary Artery Disease
https://www.readbyqxmd.com/read/26247798/comparative-associations-between-angiotensin-converting-enzyme-inhibitors-angiotensin-receptor-blockers-and-their-combination-and-outcomes-in-patients-with-heart-failure-and-reduced-ejection-fraction
#15
COMPARATIVE STUDY
Gianluigi Savarese, Magnus Edner, Ulf Dahlström, Pasquale Perrone-Filardi, Camilla Hage, Francesco Cosentino, Lars H Lund
BACKGROUND: Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are recommended in heart failure with reduced ejection fraction (HFREF), but there is limited data on ARB vs. ACE-I and their combination in unselected populations. The purpose of this study was to compare the associations between the use of ACE-I, ARB and their combination, and outcomes in HFREF. METHODS AND RESULTS: We prospectively studied 22,947 patients with HFREF (ejection fraction<40%) enrolled in the Swedish Heart Failure Registry who received ACE-I but not ARB (n=15,801, 69%), ARB but not ACE-I (n=4335, 19%), their combination (n=571, 2%) or neither (n=2240, 10%)...
November 15, 2015: International Journal of Cardiology
https://www.readbyqxmd.com/read/26093871/effects-of-withdrawing-vs-continuing-renin-angiotensin-blockers-on-incidence-of-acute-kidney-injury-in-patients-with-renal-insufficiency-undergoing-cardiac-catheterization-results-from-the-angiotensin-converting-enzyme-inhibitor-angiotensin-receptor-blocker
#16
RANDOMIZED CONTROLLED TRIAL
Kevin R Bainey, Sherali Rahim, Krystal Etherington, Michael L Rokoss, Madhu K Natarajan, James L Velianou, Sonya Brons, Shamir R Mehta
BACKGROUND: It is unclear if holding angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) prior to coronary angiography reduces contrast-induced acute kidney injury (AKI). We undertook a randomized trial to investigate the effect of holding ACEI/ARB therapy prior to coronary angiography on the incidence of AKI. METHODS: We randomly assigned 208 patients with moderate renal insufficiency (creatinine ≥ 1.7mg/dL within 3 months and/or documented creatinine ≥ 1...
July 2015: American Heart Journal
https://www.readbyqxmd.com/read/26034118/risk-factors-treatment-and-prognosis-in-men-and-women-with-heart-failure-with-and-without-diabetes
#17
COMPARATIVE STUDY
Isabelle Johansson, Ulf Dahlström, Magnus Edner, Per Näsman, Lars Rydén, Anna Norhammar
OBJECTIVE: To test the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart failure (HF) with and without diabetes in the Swedish Heart Failure Registry. METHODS: Patients with (n=8809) and without (n=27 465) type 2 diabetes (T2DM) included in the Swedish Heart Failure Registry (2003-2011) were followed for mortality during a median follow-up of 1.9 years (range 0-8.7 years). All-cause mortality, differences in background and HF characteristics were analysed in women and men with and without T2DM and with a special regard to different age groups...
July 2015: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/25827194/diabetes-mellitus-in-patients-presenting-with-cardiovascular-events-descriptive-analysis-from-a-tertiary-heart-hospital-over-a-22-year-period
#18
Ayman El-Menyar, Hassan Al-Thani, Ahammed Mekkodathil, Shaban Mohammed, Rajvir Singh, Hajar AlBinAli, Jassim Al Suwaidi
BACKGROUND: Diabetes mellitus (DM) remains a health care challenge worldwide. We evaluated the trends and outcome of DM in patients presenting with cardiovascular diseases (CVD) over a 22-year period in Qatar. METHODS AND RESULTS: A retrospective analysis was performed between 1991 and 2012, including 48,803 patients admitted to the tertiary Heart Hospital (HH). The average CVD hospitalization rate was 37 admissions per 10,000 people, of which, 2 out of 5 patients had DM...
2015: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/25801408/twenty-four-hour-heart-rate-lowering-with-ivabradine-in-chronic-heart-failure-insights-from-the-shift-holter-substudy
#19
Michael Böhm, Jeffrey S Borer, John Camm, Ian Ford, Suzanne M Lloyd, Michel Komajda, Luigi Tavazzi, Mario Talajic, Mitja Lainscak, Jan-Christian Reil, Christian Ukena, Karl Swedberg
AIMS: Analysis of 24-h Holter recordings was a pre-specified substudy of SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) for exploring the heart rhythm safety of ivabradine and to determine effects of ivabradine on 24-h, daytime, and night-time heart rate (HR) compared with resting office HR. METHODS AND RESULTS: The 24-h Holter monitoring was performed at baseline and 8 months after randomization to ivabradine (n = 298) or matching placebo (n = 304) titrated maximally to 7...
May 2015: European Journal of Heart Failure
https://www.readbyqxmd.com/read/25766855/if-home-telemonitoring-reduces-mortality-in-heart-failure-is-this-just-due-to-better-guideline-based-treatment
#20
Riet Dierckx, John Gf Cleland, Pierpaolo Pellicori, Jufen Zhang, Kevin Goode, Paola Putzu, Vennela Boyalla, Andrew L Clark
UNLABELLED: To investigate, in a 'real-world' setting, the impact of home telemonitoring (HTM) compared to usual care on achieved dose of guideline-recommended medication, hospitalisation rate and mortality in patients with heart failure (HF). METHODS: We retrospectively analyzed data on 333 patients with HF referred to a HTM service supported by a nurse-specialist (mean age 71±12 years, mean left ventricular ejection fraction (LVEF) 36 ± 11% and median N-Terminal pro B-type Natriuretic Peptide (NT-proBNP) 2,972 ng/L (interquartile range (IQR): 1,447-7,801 ng/L))...
September 2015: Journal of Telemedicine and Telecare
keyword
keyword
103281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"